腺様嚢胞がんの世界市場-2023年～2030年

市場概要

世界の腺様嚢胞がん市場は、2022年に2億2,430万米ドルに達し、2023年から2030年の予測期間中にCAGR 5.6%で成長し、2030年には3億4,460万米ドルに達すると予測されています。個別化医療へのシフトなどの動向は、世界の腺様嚢胞がん市場を独占すると予想されます。

世界の腺様嚢胞がん（ACC）市場は近年大きく成長しており、今後も上昇傾向が続くと予測されます。市場は変革期を迎えており、標的療法の使用、免疫療法やRNA療法の新たな選択肢など、いくつかの重要な動向の影響を受けています。

さらに、腺様嚢胞がんの有病率の上昇、診断技術の進歩、研究開発活動への注力の増加が腺様嚢胞がんの市場規模を押し上げています。これらの分野における診断技術の進歩により、腺様嚢胞がんの検出と診断が改善され、Ayala Pharmaceuticals社、Amgen社、CureVac AG社などの重要な競合企業が市場で積極的に活動しているため、北米地域からの需要が増加しています。

市場力学

腺様嚢胞がんの症例数の増加が腺様嚢胞がん市場の成長を牽引

腺様嚢胞がんの症例数の増加は、腺様嚢胞がん市場の拡大を促進する主要因です。これは、症例数の増加につながっている疾患に対する認識の高まりによるものです。例えば、2023年の米国臨床腫瘍学会（ASCO）の報告によると、米国では毎年約1300人がこのがんと診断されています。

さらに、腺様嚢胞がんは主に女性に多く、全症例の60％を占めています。このようにがんの発生が増加しているため、新規治療法の発見や既存薬の改善を目的とした研究開発が重視されています。このように、これらの疾患の有病率が高まっていることが、予測期間にわたって市場を牽引しています。

治験件数の増加が市場成長を牽引

腺様嚢胞がんの治療と診断に関する治験件数の増加は、この市場の主要な促進要因です。治験は、新しい治療法や診断法を発見し、それによって患者の転帰を改善する上で大きな役割を果たします。さらに、この治験から生成されたデータは、研究を促進し、国際的な共同研究を増加させる重要なゲートウェイとなります。

例えば、Memorial Sloan Kettering Cancer Centerは、Merck Sharp &Dohme LLCおよびEisai Inc.と共同で、2019年12月に開始した治験を実施しています。この試験の主な目的は、進行性腺様嚢胞がん（ACC）患者を対象にレンバチニブやペムブロリズマブなどの薬剤の試験と安全性を評価することです。現在、この治験は第II相試験であり、終了予定は2023年12月です。このように、治験の件数増加により、市場は予測可能な将来にわたって牽引していくと予想されます。

腺様嚢胞がん治療に伴う高コストが市場の成長を妨げる

腺様嚢胞がんの治療には、手術や標的療法などの薬物療法が含まれ、比較的高額になる可能性があります。そのため、この疾患を患う患者の先進治療へのアクセスは制限されています。例えば、ACC治療で使用される免疫療法薬のコストは、多くの患者にとって非常に高額であるため、潜在的に有益なこの治療オプションへのアクセスが妨げられています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 腺様嚢胞がんの有病率の増加
    • 治験数の増加
  • 抑制要因
    • 腺様嚢胞がん治療に伴う高コスト
  • 機会
    • 個別化医療の需要の増加
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 部位別

• 唾液腺
• 涙腺
• 乳腺
• その他

第8章 薬剤クラス別

• 細胞毒性薬
• チロシンキナーゼ阻害薬
• モノクローナル抗体
• その他

第9章 治療法別

• 手術療法
• 放射線療法
• 化学療法
• 標的療法

第10章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Ayala Pharmaceuticals
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Amgen
• CureVac AG
• Elevar Therapeutics
• Actuate Therapeutics
• Prelude Therapeutics
• Merck Sharp & Dohme Corp.
• Lilly USA, LLC
• Celgene Corporation
• OncoMed Pharmaceuticals

第14章 付録

Market Overview

Global Adenoid Cystic Carcinoma Market reached US$ 224.3 million in 2022 and is expected to reach US$ 344.6 million by 2030 growing with a CAGR of 5.6% during the forecast period 2023-2030. The trend such as shift towards personalized medicine is expected to dominate the global adenoid cystic carcinoma market.

The global adenoid cystic carcinoma (ACC) market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as usage of targeted therapies, and emerging immunotherapy and RNA therapy options.

Furthermore, rising prevalence of adenoid cystic carcinoma, advancements in diagnostic techniques, increase in focus on research and development activities is driving up the adenoid cystic carcinoma market size. Due to the advancements of diagnostics technologies in these fields resulting improved detection and diagnosis of adenoid cystic carcinoma is seeing an increase in demand from North American regions with significant competitors like Ayala Pharmaceuticals, Amgen, CureVac AG, and others actively operating in the market.

Market Dynamics

The Growing Prevalence of Adenoid Cystic Carcinoma to Drive the Growth of the Adenoid Cystic Carcinoma Market

The rising number of cases of adenoid cystic carcinoma is a key driver driving the adenoid cystic carcinoma market's expansion. This is due to the increase awareness about the disease that has resulted in more number of cases. For instance, according to the American Society of Clinical Oncology (ASCO) report of 2023, about 1300 people are been diagnosed with this cancer every year in U.S.

Moreover, the adenoid cystic carcinoma is mostly prevalent in women accounting 60% of all cases. Because of this increasing occurrence, there has been a greater emphasis on the research and development, with the goal of discovering novel therapeutic options and improving existing medications. Thus, owing to the growing prevalence of these condition to drive the market over the forecast period.

The Increasing Number of Clinical Trials will Drive the Market Growth

The growing number of clinical trials for adenoid cystic carcinoma treatment and diagnosis is a major driver for this market. Clinical trials play a major role in discovering novel treatment and diagnostic options thereby providing a improved patient outcomes. Moreover, the data generated from this clinical trial makes an important gateway in fostering the research, and increasing the international collaboration.

For instance, Memorial Sloan Kettering Cancer Center in collaboration with Merck Sharp & Dohme LLC and Eisai Inc. is conducting a clinical trial that has began on December 2019. The primary objective of this trial is to evaluate the study and safety of drugs such as Lenvatinib and Pembrolizumab in people with advanced Adenoid Cystic Carcinoma (ACC). Currently the trial is phase 2 and the estimated completion of trial is December 2023. Thus, owing to the increasing number of clinical trials the market is expected to drive over the foreseeable future.

The High Cost Associated with Adenoid Cystic Carcinoma Treatment will Hamper the Growth of the Market

Adenoid cystic carcinoma treatment involves surgery, medication such as targeted therapies, that can be relatively expensive. This has resulted in limited access towards advanced treatment for the patient suffering from this condition. For instance, the cost of immunotherapy drugs used in ACC treatment are very costly for many patient, thereby hindering their access to this potentially beneficial treatment option.

Segment Analysis

The global adenoid cystic carcinoma market is segmented based on location, drug class, treatment, distribution channel and region.

Owing to its Better Effectiveness, the Surgery Segment Accounted for Approximately 34.6% of the Adenoid Cystic Carcinoma Market Share

The surgery segment is poised to dominate the adenoid cystic carcinoma market as it remains a common and preferred medical treatment for adenoid cystic carcinomas owing to its effectiveness and better cure for this carcinoma. As adenoid cystic carcinoma mainly affects in the salivary gland, the surgery remains the foremost treatment option for this disease. During surgery their is removal of tumor and some of the healthy tissue around the cancer, as this cancer spreads frequently along the nerves, the surgery becomes an important segment in identifying the nerves involved in it.

Furthermore, many clinical trial are in progress involving different surgery tecniques. For instance, Ohio State University Comprehensive Cancer Center is conducting a clinical trial consisting of transoral robotic surgery (TORS) for treating adenoid cystic carcinoma it uses the the Da Vinci Robotic Surgical System for the surgery. Furthermore, radiation therapy is advised after surgery if there is an intermediate- or high-grade cancer or an adenoid cystic carcinoma, or the cancer was not removed completely. Thus, considering the above factors the segment is expected to grow over the forecast period.

Geographical Penetration

North America Accounted for Approximately 39.4% of the Market Share in 2022, Owing to the Presence of Renowed Research Institutions

North America, particularly the United States, dominates the global adenoid cystic carcinoma market due to its advanced healthcare infrastructure, presence of renowed research institute conducting research for development of novel treatment options. The region's superior medical facilities provide access to cutting-edge therapies, while intensive awareness campaigns and regular screenings contribute to improved early identification and treatment outcomes.

For instance, a 2022 article published in American Society of Clinical Oncology the University of Texas MD Anderson Cancer Center an established research center in U.S. has conducted a extensive research for this carcinoma. The research involves use of NOTCH1 inhibitors that targets NOTCH1-mutant adenoid cystic carcinoma. These inhibitors are designed from sequencing techniques and molecular analysis, that shows immense promise for patients with ACC, a rare and aggressive head and neck cancer. Therefore, owing to the above factors the market is expected to grow at faster rate in this region over the forecast period.

Competitive Landscape

The major global players in the adenoid cystic carcinoma include Ayala Pharmaceuticals, Amgen, CureVac AG, Elevar Therapeutics, Actuate Therapeutics, Prelude Therapeutics, Merck Sharp & Dohme Corp., Lilly USA, LLC, Celgene Corporation, and OncoMed Pharmaceuticals and among others.

COVID-19 Impact Analysis

The effect of COVID-19 on ACC has worsened the presenting stage of many malignancies and had a detrimental impact on their prognosis. However, rivoceranib, an oral VEGFR2 TKI, showed promising results in individuals with recurrent or metastatic ACC in a phase 2 study. COVID-19 may have an extensive effect on the standard of life and well-being of cancer patients and survivors.

Moreover, cancer patients, such as those with ACC, are more likely to develop severe COVID-19 and die from it, especially if they are older, male, have a larger number of comorbidities, have hematologic malignancies, and have just received chemotherapy. Cancer screening delays during the pandemic led to delayed detection, a higher proportion of patients being diagnosed at an advanced stage, and a higher death rate. ACC patients must adhere to strict follow-up and seek medical attention for any suspicious clinical signs since early detection improves illness prognosis.

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is having impact on the global adenoid cystic carcinoma market. The conflict has decreased access to healthcare services in Ukraine, making it harder for adenoid cystic carcinoma patients to receive critical treatment. The increased financial load on patients as a result of treatment costs and economic instability has further hampered access to care. Delayed diagnosis and treatment have also been noted as people are unwilling to seek medical help in the midst of the conflict.

These obstacles have had a detrimental impact on the worldwide adenoid cystic carcinoma market, producing slower growth than expected. However, there is potential for development, such as a greater emphasis on creating more effective treatment options and improving adenoid cystic carcinoma awareness in Ukraine. As the war ends and healthcare access improves, the market is projected to rebound. Nonetheless, the conflict's impact on the market is still enormous, necessitating continual efforts to handle the problems and opportunities it brings.

By Site

• Salivary Gland
• Lacrimal Gland
• Breast
• Others

By Drug Class

• Cytotoxic Drugs
• Tyrosine Kinase Inhibitors
• Monoclonal Antibodies
• Others

By Treatment

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On June 6, 2022, Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, stated that data from the Phase 2 ACCURACY study will be presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held on June 3-7, 2022, in Chicago, Illinois.
• On February 8, 2021, Elevar Therapeutics, Inc stated in a press release that the FDA has given Orphan Drug Designation to the small molecule tyrosine kinase inhibitor apatinib (Rivoceranib) for the treatment of the rare disease adenoid cystic carcinoma.

Why Purchase the Report?

• To visualize the global adenoid cystic carcinoma market segmentation based on location, drug class, treatment, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of adenoid cystic carcinoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available as excel consisting of key products of all the major players.

The global adenoid cystic carcinoma market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet By Site
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Treatment
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Growing Prevalence of Adenoid Cystic Carcinoma
    • 4.1.1.2. The Increasing Number of Clinical Trials
  • 4.1.2. Restraints
    • 4.1.2.1. The High Cost Associated with Adenoid Cystic Carcinoma Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Demand for Personalized Medicine
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Site

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
  • 7.1.2. Market Attractiveness Index, By Site
• 7.2. Salivary Gland*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Lacrimal Gland
• 7.4. Breast
• 7.5. Others

8. By Drug Class

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.1.2. Market Attractiveness Index, By Drug Class
• 8.2. Cytotoxic Drugs*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Tyrosine Kinase Inhibitors
• 8.4. Monoclonal Antibodies
• 8.5. Others

9. By Treatment

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.1.2. Market Attractiveness Index, By Treatment
• 9.2. Surgery*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Radiation Therapy
• 9.4. Chemotherapy
• 9.5. Targeted Therapy

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Spain
    • 11.3.7.5. Italy
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Ayala Pharmaceuticals*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Amgen
• 13.3. CureVac AG
• 13.4. Elevar Therapeutics
• 13.5. Actuate Therapeutics
• 13.6. Prelude Therapeutics
• 13.7. Merck Sharp & Dohme Corp.
• 13.8. Lilly USA, LLC
• 13.9. Celgene Corporation
• 13.10. OncoMed Pharmaceuticals

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us